| abstract |
The present invention relates to methods and compositions intended for the treatment, treatment or prevention of non-neoplastic hyperproliferative cells or excessive cell accumulation disorders, particularly disorders involving hyperproliferation of epithelial cells or endothelial cells. In one embodiment, the method of the present invention comprises the effect of one or more EphA2 agonists that bind to EphA2 and enhance EphA2 cytoplasmic tail phosphorylation and / or enhance EphA2 autophosphorylation in EphA2 agonistic cells. Including administration of an amount. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonists that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the method of the invention comprises one or more EphA2 agonists that bind to EphA2 and reduce a pathogenic cell phenotype (eg, a pathogenic epithelial cell phenotype or a pathogenic endothelial cell phenotype). Includes administration of an effective amount of the substance. In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonists that are EphA2 antibodies that bind to EphA2 at a very low K off rate. In a preferred embodiment, the substance of the invention is a monoclonal antibody. The present invention also includes a medicament comprising one or more EphA2 agonistic substances of the present invention alone or in combination with one or more other substances useful in therapy for non-neoplastic hyperproliferative cells or excessive cell accumulation disorders. A composition is provided. |